한글목차

섬망 시장 규모는 예측 기간 중 5.84%의 CAGR로 성장할 것으로 예측되고 있습니다.

고령화 인구의 증가, 식별과 진단의 향상, 기술의 진보가 시장 성장의 원동력이 되고 있습니다.

고령화는 섬망 시장의 중요한 촉진요인입니다. 전 세계 인구가 고령화됨에 따라 섬망의 유병률이 증가하고 있습니다. 노인은 기저질환, 인지장애, 다약제 병용, 입원 등의 요인으로 인해 섬망에 걸리기 쉽습니다. 신경전달물질의 변화, 인지 예비력 저하 등 노화에 따른 생리적 변화도 섬망에 취약한 요인 중 하나입니다.

인구의 고령화는 섬망의 근본적인 메커니즘을 규명하고 연령에 맞는 중재법 개발에 초점을 맞춘 혁신적인 연구 노력에 영향을 미치고 있습니다. 또한, 의료진이 노인 섬망 관리를 효과적으로 수행하기 위해 필요한 지식과 기술을 습득할 수 있도록 다학제적 협력과 훈련의 중요성도 강조되고 있습니다. 이러한 노인 인구 증가는 섬망 시장의 확대와 발전의 원동력이 되고 있습니다.

북미의 섬망 시장은 고령화와 만성질환의 증가에 의해 2022년에 최대 시장 점유율을 나타냈습니다. 이 지역의 확립된 의료 인프라와 첨단의학 연구가 섬망 관리에서 진단·치료 혁신의 성장에 기여하고 있습니다.

유럽의 섬망 시장은 제2위의 시장 점유율을 차지할 것으로 예상되고 있습니다. 국가별로는 독일이 최대 점유율을 차지하며, 프랑스가 유럽 지역에서 가장 급성장할 것으로 예측됩니다.

세계의 섬망 시장을 조사했으며, 시장의 정의와 개요, 시장 성장에 대한 영향요인 및 시장 기회의 분석, 시장 규모의 추이·예측, 각종 구분·지역별 내역, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 이그제큐티브 핸드북

제2장 시장 개요

제3장 조사 방법

제4장 시장 역학

• 성장 파라미터 매핑 : 촉진요인
  • 고령자 인구의 증가
  • 식별·진단의 개선
  • 기술적으로 첨단 치료에 대한 수요의 증가
• 과제
  • 치료비의 상승
  • 데이터 보안에 대한 위협과 엄격한 규제 준수
• 기회
  • 제약기업 및 학술기관과의 제휴

제5장 시장 요인 분석

• 밸류체인 분석
• Porter's Five Forces 분석
• COVID-19의 영향 분석

제6장 세계의 섬망 시장 : 유형별

• 과잉행동
• 저활동성
• 혼합

제7장 세계의 섬망 시장 : 진단·치료별

• 진단
  • 임상 검사
  • 이학적 검사
  • 영상 검사
• 처리
  • 항정신병약
  • 지지 요법

제8장 세계의 섬망 시장 : 최종사용자별

• 병원
• 전문 케어
• 연구 센터

제9장 세계의 섬망 시장 : 지역별

• 북미
• 유럽
• 아시아태평양
• 기타 지역

제10장 경쟁 구도

• 경쟁 대시보드
• 기업 시장 점유율 분석
• 시장의 디스럽터와 이노베이터
• 시장 리더 채택 전략
• 경쟁 벤치마킹
• 개발 건수면에서의 TOP 기업
• 주요 기업 리스트 : 지역별
• 기업 주식
• 주요 기업의 재무 비교 분석
• 주요 개발·성장 전략

제11장 기업 개요

• OTSUKA PHARMACEUTICAL CO., LTD
• MYLAN N.V
• TEVA PHARMACEUTICAL INDUSTRIES LTD
• ZYDUS GROUP
• GLENMARK PHARMACEUTICALS LTD
• PFIZER
• MYLAN N.V
• TEVA PHARMACEUTICAL INDUSTRIES LTD
• GLENMARK PHARMACEUTICALS LTD
• NOVARTIS AG

제12장 권장사항·전문가의 견해

제13장 MRFR의 제공 내용과 팀

영문목차

Market Overview

The Delirium Market is anticipated to register a CAGR of 5.84% during the review period. Developing maturing populace, further developed distinguishing proof and finding, and mechanical headways are driving the market development.

The maturing populace is a critical driver of the delirium market. As the worldwide populace encounters a segment shift towards more seasoned grown-ups, the pervasiveness of delirium increments. More seasoned people are more powerless to delirium because of variables, for example, hidden medical issue, mental debilitations, polypharmacy, and hospitalization. The physiological changes related with maturing, like modifications in synapses and diminished mental save, additionally add to the weakness to delirium. The maturing populace's effect on the delirium market is complex. Right off the bat, it prompts a more prominent number of delirium cases, provoking a higher interest for indicative instruments, mediations, and the executives' procedures.

Furthermore, the maturing populace impacts innovative work endeavors zeroed in on figuring out the fundamental systems of delirium and creating age-explicit mediations. It additionally highlights the significance of interdisciplinary joint effort and preparing to furnish medical care experts with the information and abilities fundamental for successful delirium the board in more seasoned grown-ups. In general, the developing maturing populace is a main thrust behind the extension and progression of the delirium market.

Market Segmentation

Based on kind, the Delirium Market is divided into three segments: Hyperactive, Hypoactive, and Mixed.

The segmentation of the delirium market is predicated on diagnosis and therapy, which comprises both diagnosis and treatment.

The market is divided into hospitals, specialty care, and research centers based on the end-user.

The North American Delirium market addressed the greatest market share in 2022 considering developing people and a rising in continuous disorders, there is an extended knowledge of delirium as a fundamental piece of patient thought. The region's well established clinical benefits establishment and high-level clinical assessment add to the improvement of expressive and medicinal progressions in delirium the board.

Europe Delirium market should address the second-greatest market share in light of the extraordinary prosperity courses of action and example towards organizing prosperity organizations, including directing.

The Asia-Pacific clinical consideration directing market should create at the speediest rate from 2023 to 2030. This is a direct result of the rising spending in clinical benefits, quickly creating clinical consideration establishment, creating care with respect to Delirium, and creating people in the region.

The Rest of the World integrates the Middle East, Africa, and Latin America. The chief variables affecting the advancement of Delirium are in the Middle East and Africa.

Key Market Players

The key market players are Mylan N.V (US), Otsuka Pharmaceutical Co., Ltd (Japan), Mylan N.V (US), Teva Pharmaceutical Industries Ltd (Israel), Glenmark Pharmaceuticals Ltd (India), Zydus Group (India), Pfizer (India), Teva Pharmaceutical Industries Ltd (Israel), and Novartis AG (Switzerland).

TABLE OF CONTENTS

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS

1. EXECUTIVE'S HANDBOOK

• 1.1. THE TOP PERFORMING SEGMENTS
• 1.2. KEY TRENDS SUMMARIZED
• 1.3. PRICING OUTLOOK
• 1.4. STRATEGIC INSIGHTS
• 1.5. WHO ARE THE KEY PLAYERS IN THE MARKET?

SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE

2. MARKET INTRODUCTION

• 2.1. DEFINITION
• 2.2. REPORT SEGMENTATION & SCOPE
• 2.3. REGIONAL & COUNTRY LEVEL COVERAGE
• 2.4. WHY YOU NEED THIS REPORT?

3. RESEARCH METHODOLOGY

• 3.1. RESEARCH PROCESS
• 3.2. SECONDARY RESEARCH
  • 3.2.1. DATA MINING & CONDENSATION
  • 3.2.2. SOURCES (ASSOCIATIONS, ORGANIZATIONS, MAGAZINES, PAID DATABASES)
• 3.3. PRIMARY RESEARCH
  • 3.3.1. SAMPLE SIZE (DEMAND-SUPPLY, COMPANY TYPE, DESIGNATIONS, REGION)
  • 3.3.2. SOURCES
• 3.4. FACTORIAL ANALYSIS & APPROACH SETTING
• 3.5. ESTIMATION & FORECAST MODELS
• 3.6. PRICING BASKETS
• 3.7. ANALYST HOURS & TEAM

SECTION III: QUALITATIVE ANALYSIS

4. MARKET DYNAMICS

• 4.1. INTRODUCTION
• 4.2. GROWTH PARAMETERS MAPPED - DRIVERS
  • 4.2.1. GROWING AGING POPULATION
  • 4.2.2. IMPROVED IDENTIFICATION AND DIAGNOSIS
  • 4.2.3. INCREASING DEMAND FOR TECHNOLOGICALLY ADVANCED TREATMENT
• 4.3. WHAT ARE THE CHALLENGES FACED BY INDUSTRY PARTICIPANTS?
  • 4.3.1. HIGH COST OF TREATMENT
  • 4.3.2. THREAT TO DATA SECURITY &STRICT REGULATORY COMPLIANCE
• 4.4. OPPORTUNITIES
  • 4.4.1. COLLABORATION WITH PHARMACEUTICAL COMPANIES AND ACADEMIC INSTITUTIONS
  • 4.4.2. OPPORTUNITY
  • 4.4.3. OPPORTUNITY

5. MARKET FACTOR ANALYSIS

• 5.1. VALUE CHAIN ANALYSIS
  • 5.1.1. R&D AND DESIGNING
  • 5.1.2. MANUFACTURING
  • 5.1.3. DISTRIBUTION & SALES
  • 5.1.4. POST SALES SERVICES
• 5.2. PORTER'S FIVE FORCES MODEL
  • 5.2.1. BARGAINING POWER OF SUPPLIERS
  • 5.2.2. BARGAINING POWER OF BUYERS
  • 5.2.3. THREAT OF NEW ENTRANTS
  • 5.2.4. THREAT OF SUBSTITUTES
  • 5.2.5. INTENSITY OF RIVALRY
• 5.3. COVID-19 IMPACT ANALYSIS
  • 5.3.1. IMPACT ON R&D
  • 5.3.2. IMPACT ON PRICING
  • 5.3.3. IMPACT ON REGIONS

SECTION IV: QUANTITATIVE ANALYSIS

6. GLOBAL DELIRIUM MARKET, BY TYPE (USD MILLION)

• 6.1. INTRODUCTION
• 6.2. HYPERACTIVE
  • 6.2.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY HYPERACTIVE,-2030
• 6.3. HYPOACTIVE
  • 6.3.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY HYPOACTIVE,-2030
• 6.4. MIXED
  • 6.4.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY MIXED,-2030

7. GLOBAL DELIRIUM MARKET, BY DIAGNOSIS AND TREATMENT (USD MILLION)

• 7.1. INTRODUCTION
• 7.2. DIAGNOSIS
  • 7.2.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS,-2030
  • 7.2.2. LABORATORY TESTS
  • 7.2.3. PHYSICAL EXAMINATION
  • 7.2.4. IMAGING TEST
• 7.3. TREATMENT
  • 7.3.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TREATMENT,-2030
  • 7.3.2. ANTIPSYCHOTICS
  • 7.3.3. SUPPORTIVE CARE

8. GLOBAL DELIRIUM MARKET, BY END USER (USD MILLION)

• 8.1. INTRODUCTION
• 8.2. HOSPITALS
  • 8.2.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY HOSPITALS,-2030
• 8.3. SPECIALITY CARE
  • 8.3.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY SPECIALITY CARE,-2030
• 8.4. RESEARCH CENTERS
  • 8.4.1. GLOBAL DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY RESEARCH CENTERS,-2030

9. GLOBAL DELIRIUM MARKET, BY REGION (USD MILLION)

• 9.1. INTRODUCTION
• 9.2. NORTH AMERICA
  • 9.2.1. NORTH AMERICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY COUNTRY,-2030
  • 9.2.2. NORTH AMERICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
  • 9.2.3. NORTH AMERICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
  • 9.2.4. NORTH AMERICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
  • 9.2.5. US
  • 9.2.6. US DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
  • 9.2.7. US DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
    • 9.2.7.1. US DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
  • 9.2.8. CANADA
    • 9.2.8.1. CANADA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
    • 9.2.8.2. CANADA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
    • 9.2.8.3. CANADA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
  • 9.2.9. MEXICO
    • 9.2.9.1. MEXICO DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
    • 9.2.9.2. MEXICO DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
    • 9.2.9.3. MEXICO DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
• 9.3. EUROPE
  • 9.3.1.1. EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY COUNTRY,-2030
  • 9.3.1.2. EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
  • 9.3.1.3. EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
  • 9.3.1.4. EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
  • 9.3.2. GERMANY
    • 9.3.2.1. GERMANY DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
    • 9.3.2.2. GERMANY DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
    • 9.3.2.3. GERMANY DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
  • 9.3.3. FRANCE
    • 9.3.3.1. FRANCE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
    • 9.3.3.2. FRANCE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
    • 9.3.3.3. FRANCE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
  • 9.3.4. UK
    • 9.3.4.1. UK DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
    • 9.3.4.2. UK DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
    • 9.3.4.3. UK DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
  • 9.3.5. SPAIN
    • 9.3.5.1. SPAIN DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
    • 9.3.5.2. SPAIN DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
    • 9.3.5.3. SPAIN DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
  • 9.3.6. ITALY
    • 9.3.6.1. ITALY DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
    • 9.3.6.2. ITALY DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
    • 9.3.6.3. ITALY DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
  • 9.3.7. REST OF EUROPE
    • 9.3.7.1. REST OF EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
    • 9.3.7.2. REST OF EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
    • 9.3.7.3. REST OF EUROPE DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
• 9.4. ASIA-PACIFIC
  • 9.4.1. ASIA PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY COUNTRY,-2030
  • 9.4.2. ASIA PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
  • 9.4.3. ASIA PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
  • 9.4.4. ASIA PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
  • 9.4.5. CHINA
    • 9.4.5.1. CHINA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
    • 9.4.5.2. CHINA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
    • 9.4.5.3. CHINA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
  • 9.4.6. INDIA
    • 9.4.6.1. INDIA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
    • 9.4.6.2. INDIA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
    • 9.4.6.3. INDIA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
  • 9.4.7. JAPAN
    • 9.4.7.1. JAPAN DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
    • 9.4.7.2. JAPAN DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
    • 9.4.7.3. JAPAN DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
  • 9.4.8. SOUTH KOREA
    • 9.4.8.1. SOUTH KOREA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
    • 9.4.8.2. SOUTH KOREA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
    • 9.4.8.3. SOUTH KOREA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
  • 9.4.9. AUSTRALIA
    • 9.4.9.1. AUSTRALIA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
    • 9.4.9.2. AUSTRALIA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
    • 9.4.9.3. AUSTRALIA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
  • 9.4.10. REST OF ASIA-PACIFIC
    • 9.4.10.1. REST OF ASIA-PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
    • 9.4.10.2. REST OF ASIA-PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
    • 9.4.10.3. REST OF ASIA-PACIFIC DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
• 9.5. REST OF THE WORLD
  • 9.5.1. MIDDLE EAST & AFRICA
    • 9.5.1.1. MIDDLE EAST AND AFRICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
    • 9.5.1.2. MIDDLE EAST AND AFRICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
    • 9.5.1.3. MIDDLE EAST AND AFRICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030
  • 9.5.2. LATIN AMERICA
    • 9.5.2.1. LATIN AMERICA AND AFRICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY TYPE,-2030
    • 9.5.2.2. LATIN AMERICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY DIAGNOSIS AND TREATMENT,-2030
    • 9.5.2.3. LATIN AMERICA DELIRIUM MARKET: MARKET ESTIMATES & FORECAST, BY END USER,-2030

SECTION V: COMPETITIVE ANALYSIS

10. COMPETITIVE LANDSCAPE

• 10.1. INTRODUCTION
• 10.2. COMPETITION DASHBOARD
• 10.3. COMPANY MARKET SHARE ANALYSIS,-23 (%)
• 10.4. WHO ARE THE MARKET DISRUPTORS & INNOVATORS?
• 10.5. WHAT STRATEGIES ARE BEING ADOPTED BY MARKET LEADERS?
• 10.6. COMPETITIVE BENCHMARKING
• 10.7. THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL DELIRIUM MARKET
• 10.8. LIST OF KEY PLAYERS, BY REGION
• 10.9. PUBLIC PLAYERS STOCK SUMMARY
• 10.10. COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL
• 10.11. KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 10.11.1. NEW TYPE LAUNCH/SERVICE DEPLOYMENT
  • 10.11.2. MERGER & ACQUISITION
  • 10.11.3. JOINT VENTURES

11. COMPANY PROFILES

• 11.1. OTSUKA PHARMACEUTICAL CO., LTD
  • 11.1.1. COMPANY OVERVIEW
  • 11.1.2. FINANCIAL OVERVIEW
  • 11.1.3. PRODUCT OFFERED
  • 11.1.4. KEY DEVELOPMENTS
  • 11.1.5. SWOT ANALYSIS
  • 11.1.6. KEY STRATEGIES
• 11.2. MYLAN N.V
  • 11.2.1. COMPANY OVERVIEW
  • 11.2.2. FINANCIAL OVERVIEW
  • 11.2.3. PRODUCT OFFERED
  • 11.2.4. KEY DEVELOPMENTS
  • 11.2.5. SWOT ANALYSIS
  • 11.2.6. KEY STRATEGIES
• 11.3. TEVA PHARMACEUTICAL INDUSTRIES LTD
  • 11.3.1. COMPANY OVERVIEW
  • 11.3.2. FINANCIAL OVERVIEW
  • 11.3.3. PRODUCT OFFERED
  • 11.3.4. KEY DEVELOPMENTS
  • 11.3.5. SWOT ANALYSIS
  • 11.3.6. KEY STRATEGIES
• 11.4. ZYDUS GROUP
  • 11.4.1. COMPANY OVERVIEW
  • 11.4.2. FINANCIAL OVERVIEW
  • 11.4.3. PRODUCT OFFERED
  • 11.4.4. KEY DEVELOPMENTS
  • 11.4.5. SWOT ANALYSIS
  • 11.4.6. KEY STRATEGIES
• 11.5. GLENMARK PHARMACEUTICALS LTD
  • 11.5.1. COMPANY OVERVIEW
  • 11.5.2. FINANCIAL OVERVIEW
  • 11.5.3. PRODUCT OFFERED
  • 11.5.4. KEY DEVELOPMENTS
  • 11.5.5. SWOT ANALYSIS
  • 11.5.6. KEY STRATEGIES
• 11.6. PFIZER
  • 11.6.1. COMPANY OVERVIEW
  • 11.6.2. FINANCIAL OVERVIEW
  • 11.6.3. PRODUCT OFFERED
  • 11.6.4. KEY DEVELOPMENTS
  • 11.6.5. SWOT ANALYSIS
  • 11.6.6. KEY STRATEGIES
• 11.7. MYLAN N.V
  • 11.7.1. COMPANY OVERVIEW
  • 11.7.2. FINANCIAL OVERVIEW
  • 11.7.3. PRODUCT OFFERED
  • 11.7.4. KEY DEVELOPMENTS
  • 11.7.5. SWOT ANALYSIS
  • 11.7.6. KEY STRATEGIES
• 11.8. TEVA PHARMACEUTICAL INDUSTRIES LTD
  • 11.8.1. COMPANY OVERVIEW
  • 11.8.2. FINANCIAL OVERVIEW
  • 11.8.3. PRODUCT OFFERED
  • 11.8.4. KEY DEVELOPMENTS
  • 11.8.5. SWOT ANALYSIS
  • 11.8.6. KEY STRATEGIES
• 11.9. GLENMARK PHARMACEUTICALS LTD
  • 11.9.1. COMPANY OVERVIEW
  • 11.9.2. FINANCIAL OVERVIEW
  • 11.9.3. PRODUCT OFFERED
  • 11.9.4. KEY DEVELOPMENTS
  • 11.9.5. SWOT ANALYSIS
  • 11.9.6. KEY STRATEGIES
• 11.10. NOVARTIS AG
  • 11.10.1. COMPANY OVERVIEW
  • 11.10.2. FINANCIAL OVERVIEW
  • 11.10.3. PRODUCT OFFERED
  • 11.10.4. KEY DEVELOPMENTS
  • 11.10.5. SWOT ANALYSIS
  • 11.10.6. KEY STRATEGIES

12. RECOMMENDATIONS & EXPERT INSIGHTS

• 12.1. WHAT IS THE SHORT-TERM VS LONG-TERM OUTLOOK FOR DELIRIUM MARKET?
• 12.2. WHO ARE THE PLAYERS TO LOOK OUT FOR?
• 12.3. WHAT WILL THE PRODUCT MIX LOOK IN COMING YEARS?

13. MRFR OFFERINGS & TEAM

• 13.1. CITATIONS & MEDIA
• 13.2. OUR REGIONAL REPRESENTATIVES
• 13.3. RELATED REPORTS
• 13.4. OUR DOMAIN COVERAGE